The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
Open accessAbstract
Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response.Design. Retrospective analysis.Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed.Results. At month 3, 14.9% to 29.4% of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7–16.1%) than with less frequent dosing (5.0–6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted.Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hariprasad et al 34 have reported that although long-term visual gain may be predicted by VA at month 3 of treatment, some eyes especially those with better VA had a continuing or further gain in their vision when the continued dosing was maintained.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Lalwani, G. A., Rosenfeld, P. J., Fung, A. E., Dubovy, S. R., Michels, S., Feuer, W., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.01.024 · Cited by 880
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration
Boyer, D. S., Antoszyk, A. N., Awh, C. C., Bhisitkul, R. B., Shapiro, H., & Acharya, N. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.045 · Cited by 390
Self-citationKaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361 · cited 1×
“In subgroup analyses of ANCHOR and MARINA, baseline VA was the most important predictor of VA outcomes at later time points [12, 13].”
MethodSelf-citationBoyer, D. S., Heier, J. S., Brown, D. M., Francom, S. F., Ianchulev, T., & Rubio, R. G. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.024 · Cited by 347
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Gupta, O. P., Shienbaum, G., Patel, A. H., Fecarotta, C., Kaiser, R. S., & Regillo, C. D. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.032 · Cited by 272
Research works printed but not linked: 1
- 2012, Journal of Clinical and Experimental Ophthalmology, 3, 221
Cited by
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Waldstein, S. M., Wright, J., Warburton, J., Margaron, P., Simader, C., & Schmidt-Erfurth, U. M. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.013 · Cited by 136
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A. R., Cereda, M. G., Hykin, P. G., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308166 · Cited by 130
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A. R., Cereda, M. G., Hykin, P. G., Staurenghi, G., Wittrup-Jensen, K. U., Nilsson, J., Kim, K., et al. (2016) · Eye · doi:10.1038/eye.2016.90 · Cited by 62
Erratum: Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M. K., Chakravarthy, U., Gale, R. P., Gavin, M., Ghanchi, F. D., Gibson, J., Harding, S. P., Johnston, R. L., Kelly, S. P., Lotery, A. J., et al. (2015) · Eye · doi:10.1038/eye.2015.159 · Cited by 58
Metadata
- Authors
- Hariprasad, S. M., Morse, L. S., Shapiro, H., Wong, P., & Tuomi, L.
- Affiliations
- University of Chicago (US)
- University of California Davis Medical Center (US)
- Genentech (US)
- Corresponding author
- Hariprasad, Seenu M.
- Venue
- Journal of Ophthalmology
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 2090-004X (ISSN-L)
- 2090-0058
- PMC
- PMC3515919
- OpenAlex
- W2140544410
- Cited by
- 20
- References
- 13
- Citations by year
- 2024: 2 · 2023: 1 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 6 · 2015: 4 · 2013: 1
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Ophthalmology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Genentech
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, neovascular age-related macular degeneration, dosing frequency, monthly dosing, as-needed dosing, loading dose, ANCHOR trial, MARINA trial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.1155/2012/690641
- The paper
- Hariprasad, S. M., Morse, L. S., Shapiro, H., Wong, P., & Tuomi, L. (2012). Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration. Journal of Ophthalmology. https://doi.org/10.1155/2012/690641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.